Dublin, Nov. 30, 2017 (GLOBE NEWSWIRE) -- The "Global Urinary Tract Infection (UTI) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to Research and Markets' offering.

The global urinary tract infection (UTI) treatment market is expected to grow at a CAGR of 3.2% from 2017 to 2025

In the base year 2016, North America dominated the global UTI treatment market due to large number of target population, higher treatment awareness, swift adoption of novel medications, better reimbursement policies acting as the prime contributors to the dominance of North America. On the other hand, Asia Pacific will show highest UTI treatment market growth during forecast period due to increasing healthcare awareness among general population and growing partnership of key players with local manufacturer.

The urinary tract infection (UTI) treatment market is observed to be highly competitive and comprises large number of players. However, some major market players are AstraZeneca plc., Bayer AG, Cubist Pharmaceuticals, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Johnson & Johnson, MerLion Pharmaceuticals, Osel Inc., Pfizer Inc., Rempex Pharmaceuticals and other.

Key Market Movements:

• Factors such as increase in prevalence of UTI, higher treatment compliance, changing lifestyle pattern and favorable reimbursement policies in some countries are driving the growth of UTI treatment market worldwide.
• Rising access for the treatment medication in developing countries would fuel the growth of UTI treatment market during forecast period.
• However, generic erosion, poor patient compliance in some countries and adverse effects associated with the use of medication is negatively impacting the growth of UTI treatment market.

Key Topics Covered:

Chapter 1 Preface
1.1 Report Description
1.2 Research Scope
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Global Urinary Tract Infection (UTI) Treatment Market Snapshot
2.2 Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class
2.3 Global Urinary Tract Infection (UTI) Treatment Market Share, by Geography, 2016 (Value %)

Chapter 3 Urinary Tract Infection (UTI) Treatment Market Analysis
3.1 Global Urinary Tract Infection (UTI) Treatment Market Overview
3.2 Market Dynamics
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Urinary Tract Infection (UTI) Treatment Market
3.5 Top 3 Countries

Chapter 4 Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class
4.1 Overview
4.2 Attractive Investment Proposition: Global Urinary Tract Infection (UTI) Treatment Market, by Drug Class
4.3 Penicillin
4.4 Quinolones
4.5 Cephalosporin
4.6 Sulphonamides
4.7 Tetracycline
4.8 Other

Chapter 5 Global Urinary Tract Infection (UTI) Treatment Market, By Geography

Chapter 6 Company Profiles

• AstraZeneca plc.
• Bayer AG
• Cubist Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Pharmaceuticals Ltd.
• Johnson & Johnson
• MerLion Pharmaceuticals
• Osel Inc.
• Pfizer Inc.
• Rempex Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/qp28mt/global_urinary

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Infectious Diseases Drugs, Urological Disorders Drugs

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.